Answers are grounded in this paper and cite their sources.
The efficacy and safety of risankizumab as compared with ustekinumab in patients with Crohn's disease are unknown.
No takes yet. Share an insight, caveat, or question.
Peyrin‐Biroulet et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: